Does State Medicaid Cover Testosterone Enanthate?

How Medicaid Coverage for Testosterone Enanthate Works Across States

Each state administers its own Medicaid program under federal guidelines, which means testosterone enanthate coverage depends on where you live. The majority of state Medicaid formularies include testosterone enanthate as a covered generic injectable for the treatment of male hypogonadism. Generic testosterone enanthate (200 mg/mL) remains one of the least expensive androgen formulations available, a factor that favors its inclusion on preferred drug lists.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by at least two morning serum testosterone measurements below 300 ng/dL. States typically anchor their coverage criteria to this guideline. California's Medi-Cal, for example, lists testosterone enanthate as a preferred injectable without prior authorization for diagnoses coded under ICD-10 E29.1 (testicular hypofunction). Texas Medicaid similarly covers it but requires a prior authorization form documenting two low morning testosterone levels.

States running managed-care Medicaid (roughly 40 states contract with managed-care organizations) may layer additional utilization controls on top of the state's base formulary. A Medicaid enrollee in Florida might face different paperwork depending on whether their plan is managed by Aetna Better Health, Sunshine Health, or another MCO. Checking your specific MCO's formulary is a necessary first step.

The FDA-approved prescribing information for testosterone enanthate limits the indication to males with conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). Coverage for off-label uses, including female-to-male gender-affirming hormone therapy, varies substantially and often requires separate prior authorization pathways.

Prior Authorization Requirements by State

Prior authorization (PA) is the single biggest barrier between a Medicaid prescription and a filled vial. Roughly 15 to 20 state Medicaid programs require PA for testosterone enanthate, though the exact number shifts as states update formularies annually.

Standard PA criteria across these states follow a recognizable pattern. The prescriber must document a serum total testosterone level below 300 ng/dL drawn on two separate mornings, symptoms consistent with hypogonadism (fatigue, decreased libido, erectile dysfunction, loss of muscle mass), and the absence of contraindications such as untreated polycythemia, severe sleep apnea, or active prostate cancer. The Endocrine Society guideline specifies morning draws because testosterone follows a circadian rhythm, peaking between 6:00 and 10:00 AM.

A 2016 analysis published in the Journal of Clinical Endocrinology & Metabolism found that prior authorization programs for testosterone reduced inappropriate prescribing by 20% to 30% without significantly delaying access for men meeting clinical criteria [1]. PA turnaround times average 48 to 72 hours in most states, though some states guarantee a decision within 24 hours for urgent requests.

States without PA for testosterone enanthate include (as of recent formulary publications): California, Ohio, Michigan, and Oregon. States with PA requirements include New York, Pennsylvania, Illinois, and Georgia. These lists change. Always verify against your state's current preferred drug list (PDL), which is public and typically posted on the state Medicaid agency's website.

Formulary Tier Placement and What It Means for Your Copay

Testosterone enanthate sits on a preferred generic tier in the majority of state Medicaid formularies, which translates to the lowest possible copay. Federal Medicaid rules cap copayments for preferred generics at $4 for most enrollees with incomes below 150% of the federal poverty level, per 42 CFR § 447.54.

Here is what tier placement typically looks like across state programs. Tier 1 (preferred generic) means the lowest copay, usually $1 to $4. Tier 2 (non-preferred generic) pushes the copay to $4 to $8. Tier 3 (preferred brand) would apply to brand-name Delatestryl, which is rarely stocked and substantially more expensive.

Because generic testosterone enanthate 200 mg/mL is manufactured by multiple companies (Perrigo, Hikma, Sun Pharma, and others), competition keeps the average wholesale price low. Medicaid programs benefit from federal rebate agreements under the Medicaid Drug Rebate Program, which reduces the net cost to the state even further [2].

For enrollees in states that place testosterone enanthate on a non-preferred tier, a prescriber can typically submit a formulary exception request. The most effective approach: attach lab results, the Endocrine Society guideline recommendation, and documentation that the patient has tried and failed (or has a contraindication to) any preferred alternatives the state lists.

Step Therapy: When Your State Requires a Topical Trial First

Some Medicaid programs impose step therapy, requiring a trial of topical testosterone (gel or patch) before approving injectable testosterone enanthate. The clinical rationale is thin. No randomized trial has demonstrated superiority of topical over injectable testosterone for hard clinical endpoints.

The landmark Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, used AndroGel 1% (topical) as the intervention. The trials showed improvements in sexual function, walking distance, and bone mineral density over 12 months [3]. These results, while specific to topical formulations, established the efficacy of testosterone replacement broadly and are frequently cited by Medicaid programs to justify topical-first policies.

In practice, many patients and clinicians prefer injectables for several reasons. Adherence is simpler with biweekly injections versus daily gel application. Cost is lower: generic testosterone enanthate runs approximately $70/month cash-pay versus $200 to $400/month for brand-name gels. Transfer risk (skin-to-skin contact exposing partners or children to testosterone) is eliminated with injections. The FDA issued a safety communication warning about secondary exposure from topical testosterone products, which strengthens the clinical case for requesting an injectable-first exception.

To bypass step therapy, a prescriber can document one of the following: prior adverse reaction to topical testosterone, a household member at risk for secondary exposure (children, pregnant partner), or inability to adhere to daily application due to occupational or physical limitations. Most state Medicaid programs accept these as valid exceptions.

How to Appeal a Medicaid Denial for Testosterone Enanthate

A denial is not the end of the road. Every state Medicaid program provides a fair-hearing process guaranteed by federal law under 42 USC § 1396a(a)(3). The process follows a predictable sequence.

First, request the denial in writing. The denial letter must specify the clinical reason, typically insufficient documentation, off-label use, or failure to complete step therapy. Second, file a written appeal within 30 to 60 days (the exact window varies by state). Third, include supporting documentation: two morning testosterone levels below 300 ng/dL, a letter of medical necessity from the prescribing physician, relevant Endocrine Society guideline excerpts, and records of any failed alternative therapies.

Success rates on appeal are meaningful. A 2019 analysis of Medicaid pharmacy appeals in five states found that 40% to 55% of testosterone-related denials were overturned on first appeal when accompanied by complete lab documentation and a guideline-based letter of medical necessity [4]. The most common reason for denial being upheld was incomplete paperwork, not clinical ineligibility.

If the first-level appeal fails, enrollees can request a state fair hearing, which is an administrative law proceeding. Enrollees have the right to present evidence, call witnesses, and be represented by an advocate. Legal aid organizations in most states provide free assistance for Medicaid fair hearings.

"For patients with clearly documented hypogonadism, persistence through the appeal process almost always results in coverage," noted a 2020 policy review in the American Journal of Men's Health examining Medicaid access barriers to testosterone replacement therapy [5].

Off-Label Uses and Coverage Gaps

Medicaid coverage for testosterone enanthate is anchored to the FDA-approved indication of male hypogonadism. Off-label prescribing exists in several clinical scenarios, and coverage for these uses ranges from difficult to obtain to functionally unavailable.

Gender-affirming hormone therapy represents the largest off-label use category. As of 2025, approximately 25 states and the District of Columbia have Medicaid programs that explicitly cover gender-affirming hormone therapy, including testosterone for transmasculine individuals. Coverage policies vary: some states require a gender dysphoria diagnosis (ICD-10 F64.0), a letter from a mental health provider, and adherence to World Professional Association for Transgender Health (WPATH) standards. Other states have removed mental health documentation requirements.

States that do not explicitly cover gender-affirming care may still approve testosterone enanthate if the prescriber frames the PA request around documented low testosterone levels and symptomatic criteria, regardless of the patient's gender identity. This approach works in some states but not all, and the ethical and practical complexities deserve a direct conversation with the prescribing clinician.

Weight loss is not an FDA-approved indication for testosterone enanthate, and no state Medicaid program covers it for this purpose. The TRAVERSE trial (NEJM 2023, N=5,246) examined cardiovascular safety of testosterone in men with hypogonadism and established cardiovascular disease or high cardiovascular risk. While treated men showed modest reductions in fat mass, the trial was designed as a safety study, not a weight-loss efficacy trial [6]. Medicaid will not approve testosterone based on weight management goals alone.

Reducing Out-of-Pocket Costs on Medicaid

Even with Medicaid coverage, practical cost barriers exist. Here are concrete strategies to minimize them.

Verify your MCO's formulary before your appointment. State Medicaid formularies and MCO-specific formularies are different documents. Your MCO's version is the one that determines your copay and PA requirements. Most MCOs publish searchable formularies online.

Use the state's Medicaid pharmacy hotline. Every state Medicaid program operates a pharmacy help desk that can confirm coverage status for a specific NDC (National Drug Code) in real time. This takes five minutes and eliminates guesswork.

Manufacturer savings cards cannot be combined with Medicaid. Federal anti-kickback statutes prohibit the use of manufacturer copay cards or coupons alongside any federally funded insurance, including Medicaid. Attempting to use one may trigger a compliance flag.

Consider a 340B pharmacy. Federally qualified health centers (FQHCs) and certain hospitals purchase drugs at steep discounts under the 340B Drug Pricing Program. If your prescriber is affiliated with a 340B-eligible entity, your out-of-pocket cost may drop to $0 to $10 per vial.

For cash-pay comparisons, GoodRx and similar discount platforms show testosterone enanthate 200 mg/mL (1 mL vial) at $30 to $70 at major chain pharmacies. If your Medicaid copay exceeds this range (unlikely but possible in non-preferred tier situations), paying cash and using a discount card might be cheaper. Ask the pharmacist to run both options.

Monitoring Requirements That Affect Ongoing Coverage

Medicaid programs that require prior authorization typically mandate re-authorization every 6 to 12 months. Maintaining coverage requires ongoing lab monitoring that aligns with Endocrine Society recommendations.

The standard monitoring schedule: check serum total testosterone 3 to 6 months after starting therapy (trough level, drawn just before the next injection), then every 6 to 12 months. Hematocrit should be measured at baseline, at 3 to 6 months, and annually. Testosterone therapy increases erythropoiesis; the Endocrine Society recommends withholding therapy if hematocrit exceeds 54% [7]. PSA should be measured at baseline and at 3 to 12 months in men over 40, with a referral to urology if PSA rises above 4.0 ng/mL or increases by more than 1.4 ng/mL over 12 months.

A 2020 retrospective cohort study of 44,335 men initiating testosterone therapy found that only 37% received recommended baseline lab monitoring [8]. Incomplete monitoring is both a clinical safety issue and a practical coverage issue: without updated labs, a PA renewal request is likely to be denied.

Keep copies of every lab result. When PA renewal time comes, having a complete lab history ready for submission reduces the chance of a lapse in coverage.

Serum testosterone target on therapy is 400 to 700 ng/dL measured at trough. If levels remain below 400 ng/dL on standard dosing (200 mg every two weeks), the prescriber can request a dose increase or shorter injection interval, both of which may require a separate PA in some states.